RankAlpha logo
Back to Rankings

EDIT

Editas MedicineB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The constructive case is that EDIT-401 has specific, dated milestones, management still guides to an IND/CTA by mid-2026 and early human proof-of-concept by year-end 2026, and the company reported cash runway into Q3 2027, limiting immediate financing pressure if timelines hold [#PR-2026-03-09] [#10-K-2026-03-09].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -3.8.
What can break
Auditor transition creates incremental disclosure or sentiment noise despite no stated disagreements
Momentum
82
Value
41
Sentiment
61
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.10 · Bull $4.80 · Bear $1.90
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $3.90
Why
Momentum82 · Δ7d -3.8
Value41 · Δ7d +0.1
Sentiment61 · Δ7d -19.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
82
34% active weight
Current posture
7d trendImproving
Δ7d
-3.8
Δ21d
-3.8
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
61
33% active weight
Current posture
7d trendSoftening
Δ7d
-19.7
Δ21d
-2.4
Why this grade

Composite grade B. Momentum 81.7 / Value 41.1 / Sentiment 61.2

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$512.56M
Beta
2.15
Shares Out
97.62M
P/E (TTM) · Derived
-1.8
P/S (TTM)
4.19
P/FCF (TTM) · Derived
-2.47
Rev YoY
+12265.6%
EPS YoY
+63.0%
Gross Margin
-
Op Margin
-428.7%
Net Debt
-$212.48M
Current Ratio
2.86
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology